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50kDa chitosan was conjugated with folate, a speciﬁc tissue-targeting ligand. Nanoparticles such as chitosan-DNA and folate-
chitosan-DNA were prepared by coacervation process. The hydrodynamic intravenous injection of nanoparticles was performed
in the right posterior paw in normal and arthritic rats. Our results demonstrated that the ﬂuorescence intensity of DsRed detected
was 5 to 12 times more in the right soleus muscle and in the right gastro muscle than other tissue sections. β-galactosidase gene
expression with X-gal substrate and folate-chitosan-plasmid nanoparticles showed best coloration in the soleus muscle. Treated
arthritic animals also showed a signiﬁcant decrease in paw swelling and IL-1β and PGE2 concentration in serum compared
to untreated rats. This study demonstrated that a nonviral gene therapeutic approach using hydrodynamic delivery could help
transfect more eﬃciently folate-chitosan-DNA nanoparticles in vitro/in vivo and could decrease inﬂammation in arthritic rats.
1.Introduction
Human diseases can be treated by the transfer of therapeutic
genes (transgene) into speciﬁc cells or tissues of patients to
correct or supplement defective, causative genes. The success
of gene therapy depends on the ability to deliver therapeutic
DNA or siRNA or other genetic materials to target site.
Viral vectors (e.g., adenovirus) are very eﬀective in term
of transfection eﬃciency, but they have limitations in vivo,
particularly by their safety concern and nontissue-speciﬁc
transfection. Nonviral gene transfer systems are limited by
their lower gene transfer eﬃciency, low tissue speciﬁcity,
and transient gene expression [1, 2]. Cationic polymers,
such as chitosan (Ch), are promising candidates for DNA
transport in nonviral delivery systems [3, 4]. The enabling
characteristics of Ch-DNA nanoparticles include biocom-
patibility, multiple ligand aﬃnity, and a capacity of taking
up large DNA fragments, while remaining small in size [5].
Genes can be delivered systemically (intramuscularly, intra-
venously, subcutaneously, or, in animals, intraperitoneally).
Otherwise, hydrodynamic-based gene delivery oﬀers a con-
venient, eﬃcient, and powerful means for high-level gene
expression in animals [6–8]. The highly eﬀective delivery
of naked plasmid into body or tissue with hydrodynamic
limb vein injection technique has already been demonstrated
for the treatment of muscular dystrophy [9]. However, the
mechanism of hydrodynamic injection aiding the delivery of
chitosan-based nanoparticles into targeted tissue and the use
of this approach in other disease, treatment such as arthritis
is unclear.2 Journal of Biomedicine and Biotechnology
Rheumatoid arthritis (RA) is a chronic, systemic autoim-
mune disorder that causes the immune system to attack
the joints, where it causes inﬂammation (arthritis)a n d
destruction. Other problems may also develop, including
inﬂammation of blood vessels (vasculitis), the development
of bumps (called rheumatoid nodules) in various parts of
the body, lung disease and blood disorders. The recent
report demonstrated that the muscle strength loss is strongly
associated with the presence and duration of an inﬂam-
matory state like rheumatoid arthritis [10]. Interleukin-
1 (IL-1), a key proinﬂammatory factor which consists of
2 subtypes, including IL-1α and IL-1β,i sp r o d u c e db y
monocytes macrophages. IL-1α remains mostly intracellular
(or expressed on the cell surface), while IL-1β is secreted
into the extracellular space [11]. Prostaglandin E2 (PGE2)i s
consideredtobeofgreatimportanceinpathologyofRA[12].
IL-1β has been implicated in the pathological mechanisms
of synovial tissue proliferation and joint destruction in
RA [2, 11, 13]. Its physiologically competitive agent, IL-
1 receptor antagonist (IL-1Ra), has been proven to act
as a powerful inhibitor [14]. Several therapeutic studies
on the use of recombinant IL-1Ra, as an external source
agent, have demonstrated its positive eﬀect in controlling
inﬂammation and symptoms of RA in animal models and
in clinical practice [15, 16]. Folate receptors (FR) are
o v e r e x p r e s s e do nm a n yh u m a nc a n c e rc e l ls u r f a c e s ,a n d
the nonepithelial isoform FR(β) is expressed on activated
synovial macrophages present in large numbers in RA [17].
Folate-mediated transfection has been shown to facilitate
DNA and nanoparticle internalization into cells through
membrane receptors for higher transfection yields both in
vitro and in vivo [18].
I nt h i ss t u d y ,5 0k D ac h i t o s a nw a sc o n j u g a t e dw i t hf o l i c
acid (Fa), a speciﬁc tissue-targeting ligand. Nanoparticles
such as chitosan-DNA (Ch-DNA) and Chitosan-folate-DNA
(Ch-Fa-DNA) were prepared by coacervation process. The
hydrodynamic limb intravenous injection of nanoparticles
was performed in the right posterior paw in rats. The ﬁrst
objectivewastodeterminethedistributionofthesenanopar-
ticles in normal rats following hydrodynamic injection. The
second objective of the study was to examine the in vivo
anti-inﬂammaory eﬀects of nanoparticles of plasmid IL-1Ra
DNA complexed to the Ch or Ch-Fa in an adjuvant-induced
arthritis (AIA) rat model.
2.MaterialsandMethods
All animal experiments were approved by the Animal Ethics
Committee of the Hˆ opital du Sacr´ e-Coeur de Montr´ eal.
2.1. Synthesis of Chitosan-Folate Conjugate. Chitosan (Ch)
(Wako-10,degreeofdeacetylation(DD)85%,Mw = 57kDa)
was purchased from Wako Chemicals USA (Richmond, VA).
Folic acid (Fa) was purchased from Sigma-Aldrich Chemical
(St-Louis, MO, USA). α-amino, ω-carboxyl poly(ethylene
glycol) (NH2-PEG-COOH, Mw = 3,400Dalton) was pur-
chased from Shearwater Inc. (Dallas, TX, USA). Ch was
further deacetylated by treating with concentrated NaOH
solution (50%) to obtain ∼96% deacetylation degree accord-
ing to the reported procedure [19]. To prepare the Ch-
Fa conjugate, folic acid was ﬁrst attached to NH2-PEG-
COOHviathewell-knowncarbodiimidechemistrytoobtain
folate-PEG-COOH. Then, the folate-PEG-COOH was again
activated by N,N -Dicyclohexylcarbodiimide (DCC) and
N-hydroxysuccinimide (NHS) to convert to the reactive
intermediate folate-PEG-CO-NHS and subsequently grafted
onto chitosan to achieve the folate-PEG-chitosan conjugate
[20]. The level of folate-PEG incorporation was determined
to be 1.1mol% with respect to the glucosamine unit of
chitosan by UV-Vis spectroscopy using folic acid as standard
(theextinctioncoeﬃcient(λ363nm)offolicacidisdetermined
to be 6165M−1 cm−1 in pH 7.4 phosphate buﬀer (0.1M)).
2.2.IL-RaPlasmidConstruction. Weusedhumaninterleukin
1 receptor antagonist as a curing agent, with its secretive
variant (sIL-1Ra, 177aa, NM 173842 X52015, GenBank). We
subcloned this gene by PCR with oligos carrying HindIII
and XbaI sites (IL-1RaH3 CCAAGCTTGAATGGAAATCT-
GCAGAGGCC, IL-1RaH4 GCTCTAGACTGGGCA GTAC-
TACTCGTCCTCC), using genomic DNA of macrophage
diﬀerentiated from monocyte cell line THP1 stimulated
with PMA as PCR DNA template. Then, PCR product
was inserted in the mammalian expression vector pCDNA3
(Invitrogen, Burlington, ON, Canada) that drives overex-
pression of gene with CMV promoter. To reduce the size
of pDNA, the region of PvuII-PvuII was deleted. Final
plasmid(3.8kb)includingtargetedgenewasveriﬁedbyDNA
sequencing.
2.3. Ampliﬁcation and Puriﬁcation of Plasmid DNA. The
other plasmids used in this study were VR1412 and pDsRed.
The plasmid DNA VR1412, encoding the β-galactosidase (β-
gal) reporter gene with a CMV promoter and a backbone
size of 8,100kb, was obtained from VICAL Inc. (San Diego,
CA,USA).TheplasmidpDsRedencodingtheredﬂuorescent
protein was obtained from Clonetech (Mountain View, CA,
USA).
TheplasmidDNAsweremultipliedwithEscherichiaColi
bacteria then isolated and puriﬁed using the QIAGEN Plas-
mid Mega Kit according to the manufacturer’s instruction
(Qiagen, Mississauga, ON, Canada). The puriﬁed plasmid
was resuspended in water. The purity was conﬁrmed with
0.8% agarose gel electrophoresis. The DNA concentration
was measured by UV absorption at 260nm with a UV-
visible 1601 spectrophotometer from Shimadzu (Columbia,
M D ,U S A ) .A l lb a c t e r i aw e r ea l lg r o w ni nG I B C OI n v i t r o g e n
Corporation Lennox L Broth Base (Invitrogen Canada Inc.,
Burlington, ON, Canada).
2.4. Nanoparticle Synthesis. Ch or Ch-Fa was dissolved with
low heating (below 45◦C) in a 20-mM acetic solution at pH
5.5. The solution was then adjusted to a ﬁnal concentration
of 0.02% chitosan in 5mM acetic acetate and passed through
a 0.22-μm ﬁlter. The plasmid DNA (β-gal, DsRed, and IL-
1Ra plasmid DNAs) employed for synthesis was a solution
of 200μg DNA/ml of 4.3mM sodium sulfate solution. AfterJournal of Biomedicine and Biotechnology 3
heating to 55◦C, 100μl of the DNA solution was added to
100μl of Ch or Ch-Fa solution and vortexed immediately at
maximum speed for 1min [21]. The nanoparticle solutions
producedweredeployedforstirring30minutesandallowing
standing one hour before transfection without further
modiﬁcation. Two kinds of nanoparticles were synthesized:
Ch-DNA and Ch-Fa-DNA.
2.5. In Vitro Tranfection Test. KB cells obtained from Amer-
ican Type Culture Collection (ATCC) (Rockville, MD, USA)
were used for transfection in the media with or without
folic acid supplement. On 24-well plates at a density of
50,000cells/well in 1ml of Roswell Park Memorial Institute
(RPMI), 1640 medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (PS). Next day,
medium was replaced with fresh RPMI medium 1640 or
RPMI medium 1640 without folic acid, without FBS in two
type media. After 2 hours, KB cells received 500μls o l u t i o n
of Ch- or Ch-Fa- plasmid IL-1Ra DNA nanoparticles (con-
taining 5μg human IL-1Ra plasmid DNA) in the presence or
absence of folic acid supplement. After another two hours,
0.5ml complete RPMI 1640 medium was added in each well.
Theplateswerekeptinacellculturalincubatorwith5%CO2
at 37◦C. After 24 hours, cell culture media and cells were
collected separately for later analysis.
2.6. Hydrodynamic Limb Vein Injection of Nanoparticles.
THE hydrodynamic intravenous injection was performed in
the right posterior paw, as previously published [22–24].
Nanoparticle solutions were adjusted to physical osmolarity
with 18% sterile NaCl just before injection. The injection
point was located in the great saphenous vein inside the
leg, in direction of the knee. A tourniquet was located
above the knee forcing the solution back into the smaller
leg veins and ending up in muscle tissue cells. The 4ml
transfection solution (containing 200μg DNA) was injected
into about 200g rats, at a speed of 10ml/minute, with
infusion/withdrawal pump Model 940 (Harvard Apparatus,
Millis, MA, USA). The cuﬀ was kept in place for one minute
after injection. The eyes were humidiﬁed with Liquiﬁlm
Tears eyes drops from Allergan (Markham, ON, Canada).
2.7. In Vivo Organ Distribution Study by DsRed Protein Fluo-
rescence Measurements. The female Lewis rats were injected
with the hydrodynamic technique via the femoral vein with
DesRed plasmids DNA, coding for ﬂuorescent emitting
proteins, measurable by detecting the emitted DsRed ﬂuo-
rescence wave, with a maximum excitation at 555nm and
maximal emission at 583nm. We used 9 female Lewis rats
to administer DsRed plasmid (containing 200μgD N A / r a t )
alone via the hydrodynamic technique by the femoral vein,
towards the direction of the knee. 3 experimental groups
formed 3 rats for control, 3 rats for hydrodynamic injection,
and 3 rats for normal femoral intravenous injection. The
rats were sacriﬁced 6 to 8 days following the injection; the
tissue sections of liver, kidney, gluteus superﬁcialis muscle,
and diﬀerent skeletal muscle groups of two hind limbs
(femoris bicep, soleus, and gastro) were removed, cleaned by
dipping it in clean phosphate buﬀered saline (PBS) solution,
homogenised with Polytron, and centrifuged at 3000rpm.
The samples suspensions were then stored in −80◦C until
the day the measurements are done. The ﬂuorescence
density was detected by Photon Technology International
(PTI) spectroﬂuorometer (Birmingham, NJ, USA). Protein
determination was performed by the bicinchoninic acid
method [25].
2.8. β-Gal Staining with X-Gal Substrate in Soleus Muscle.
The female Lewis rats were injected with the hydrodynamic
technique via the femoral vein with 200μgn a k e dβ-gal
plasmids DNA (3 rats), Ch-β-gal plasmids DNA (3 rats) and
Ch-Fa-β-gal plasmids DNA (3 rats), respectively. The rats
were sacriﬁced 3 days following the injection. The sampled
tissues (soleus muscles) were to be dissected into an ice cold
PBSsolutioncontaining2mMMgCl2.Theﬁxationprocessis
donebydippingthem,for30minutesandmore,inasolution
composed of 0.5% glutaraldehyde, reputed for its superior
staining and endogenous enzyme preservation activity, up
to the confounding point of the signal, compared to the
other wayby using paraformaldehyde.It is important to note
that the enzyme coding β-gal can be overﬁxed. Afterwards,
it is very important to carefully rinse of residual ﬁxatives,
which can inhibit the enzyme, by rinsing them many times
with PBS. At some point, overnight rinsing can be done.
The X-gal stock was diluted into the X-gal Reaction Buﬀer
(40mg/ml in die methyl). The tissues were then incubated
in it for 2–4 hours at 37◦C before getting rinse in PBS. The
viewing step was done under the bright ﬂuorescent white
light for optimal visualisation and analysis. One of section of
specimenswereembeddedinparaﬃn,sectioned,andstained
for β-galactosidase protein expression stained with its cor-
responding polyclonal antibody (Sigma-Aldrich, St-Louis,
MO, USA) after hydrodynamic Ch-Fa- plasmid β-gal DNA
injection. The staining was undertaken with DAKO liquid
DAB+ substrate-chromogen system kit (DAKO, Carpinteria,
CA, USA) as directed by the manufacturer. Each section was
examined under a light microscope (Zeiss Axio-Imager Z1,
Carl Zeiss MicroImaging GmbH, G¨ ottingen, Germany) at
x20 magniﬁcation and photographed with a Zeiss AxioCam
camera and Axio-Vision software (version 4.0).
2.9. Adjuvant-Induced Arthritis (AIA) Rat Model. Arthritis
was induced in 150 to 200g female Lewis rats (Charles
Rivers, Montreal, QC, Canada). Brieﬂy, on day 1, rats were
anaesthetized with 0.2ml 0.5% ketamine and 0.5% xylazine
hydrochloride, and 0.5mg of heat-killed M butyrium sus-
pended in mineral oil (5mgml, Difco, MI, USA) was injected
intradermically into the right hind foot. Disease develops
around10–45daysafterinjectionandgenerallysubsidesafter
a month. Arthritis usually develops in all treated animals,
as evidenced by dramatic swelling in the injected paws and
progressive swelling in all uninjected paws.
2.10. Experimental and Control Groups under Study. A
control group (naked DNA, n = 5), a Ch-plasmid IL-1Ra
DNA nanoparticles group (n = 5), and a Ch-Fa-plasmid IL-
1Ra DNA nanoparticles group (n = 7 )w e r ei n j e c t e do nd a y4 Journal of Biomedicine and Biotechnology
Figure 1: Hydrodynamic injection on hindlimb of rat. The
experimental detail of hydrodynamic injection procedure was given
in section of Materials and Methods.
18postAIAinduction.Anontreatedgroup(RA)(n = 5)was
used as an untreated control. All animals were sacriﬁced on
day 35 and clinical results were compared among the groups.
The evaluation of reduced adjuvant-induced arthritis was
done by evaluating ankle inﬂammation, decreased articular
index scores, ankle circumferences, and sequential calliper
measurements of the ankle joints.
2.11. Blood Samples. While under anesthesia, 7–9ml of
whole rat blood was obtained by heart puncture. Blood was
gelled at room temperature then sera were separated by
centrifugation at 6000rpm for 10 minutes. Sera were kept
separately at −80◦C until assays.
2.12. Enzyme-Linked Immunosorbent Assay (ELISA) Analysis.
IL-1Ra detection in culture medium and rat sera was carried
out with ELISA kit (R&D Systems, Minneapolis, MN, USA).
Blood serum samples were diluted 5–10 times in assay
diluents (BioFX, Owings Mills, MD, USA). 100ul of dilution
were added in 96 wells plates. No special treatment was
necessaryforstandardseries.Therestoftheprocessfollowed
the kit provider’s protocol. Rat PGE2 and Il-1β were detected
with ELISA kit (R&D Systems), by diluting blood serum
samples 100 times with PBS buﬀer containing 1% bovine
serum albumin (BSA).
2.13. Statistical Analyses. A l lv a l u e sa r ee x p r e s s e da sm e a n s
± SD and were subjected to t-test and one-way ANOVA
analysis. A value of 0.05 was considered signiﬁcant.
3. Results
3.1. Nanoparticle Characterization. All nanoparticle size
averaged 108nm. Zeta potential remained stable for all
nanoparticles between +4 and +6mV.
3.2. Eﬃcient Hydrodynamic Limb Intravenous Injection. Rats
were injected with the hydrodynamic technique (Infu-
sion/Withdrawal Pump Model 940 from Harvard Apparatus
co., inc., Millis, Mass., USA) via the right femoral vein,
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Figure 2: In vivo organ distribution study by DsRed protein
ﬂuorescence measurements. The normal female Lewis rats were
allocated to 3 groups and each consisting of 3 animals. One group,
serving as normal controls, received 4ml of saline injected with
the hydrodynamic technique via the femoral vein. Another two
Groups received 200μg DsRed plasmids DNA prepared with 4ml
saline injected by normal femoral vein injection and hydrodynamic
femoral vein injection, respectively. The rats were sacriﬁced 6 to
8 days following injection. The tissue sections of liver, kidney,
and skeletal muscle were removed, cleaned, and homogenised. The
samples suspensions were then stored in −80◦C until the day
the measurements are done. The DsRed plasmids DNA, coding
for ﬂuorescent emitting proteins, were measured by detecting the
emitted DsRed ﬂuorescence wave, with a maximum excitation at
555nm and maximal emission at 583nm. The skeletal muscle
groups included gluteus superﬁcialis (GS), Femoris Bicep of left
and right hindlimbs (Left BF and Right BF), soleus of left and
right hindlimbs (Left S and Right S), and gastro of left and right
hindlimbs (Left G and Right G). Values were shown as mean ±
SEM of normalised DsRed ﬂuorescence/protein (mg) of 3 rats of
each group. All values were subjected to t test and one-way ANOVA
analysis. A value of 0.05 was considered signiﬁcant. The highest
value of ﬂuorescent spectra (right soleus muscle section) is set as 1.
toward the direction of the knee (Figure 1). Before perform-
ingtheinjection,asmallcutwillbedoneontheskincovering
the vein. This lowers the diﬃculty level when it comes to
inserting the needle into the vein. In addition, the leg is
bound tightly, above the knee level with a tourniquet to force
the solution back into the smaller leg veins and end up in
tissue cells. This is very crucial since that is what causes the
hydrodynamicpressure,hencethewholepointofthistypeof
injection. Once the needle is properly inserted, the injection
machineisturnedonanditsspeedissettothree,around0.3-
0.4ml/sec. After the injection, only the needle is taken out;
the elastic binder stays for an extra minute to let the plasmid
settle in. For each rat, around 4ml of the injection solution is
needed; as a precaution, 5ml is set per rat.
3.3. Organ Distribution of Plasmid DNA by Hydrodynamic
Limb Intravenous Injection. To determine the tissue uptake
of plasmid DNA following hydrodynamic injection, we used
9 female Lewis rats to administer DsRed plasmid alone via
the hydrodynamic technique by the femoral vein, towards
the direction of the knee. 3 experimental groups formed 3
rats for control, 3 rats for hydrodynamic injection, and 3Journal of Biomedicine and Biotechnology 5
No treated DNA Ch-DNA Ch-Fa-DNA
123 4
(a)
(b)
Figure 3:β-galstainingwithX-Galsubstrateinsoleusmuscle.Four
groups (each consisted of 3 rats) of the normal Lewis rats treated
with the hydrodynamic femoral intravenous injection of saline or
200μgn a k e dβ-gal plasmid, Ch-β-gal plasmid DNA, and Ch-Fa-
β-gal plasmid DNA, respectively. Soleus muscle were isolated and
visualized for β-gal gene expression with X-gal substrate incubation
3 days post injection. (a) Shows the scanned images from the rat
soleus muscles. (1) nontreated controls, (2) naked plasmid β-gal
DNA injected, (3) Ch-plasmid β-gal DNA nanoparticles injected,
and (4) the Ch-Fa-plasmid β-gal DNA nanoparticles injected rats.
(b) Shows soleus muscle histological cross-sectional patterns of
β-galactosidase protein expression stained with its corresponding
antibody after hydrodynamic Ch-Fa- plasmid β-gal DNA injection
(dark brown staining).
rats for normal femoral intravenous injection. The rats were
sacriﬁced 6 to 8 days following the injection; speciﬁc DsRed
plasmid expressed red ﬂuorescent protein expression was
measured by spectroﬂuorometer in various tissue extracts
(Figure 2). The highest level of red ﬂuorescent protein
was observed in the soleus muscle of the right legs of
hydrodynamic injected rat group. The diﬀerent sampled
organs also show much lower red ﬂuorescence intensities,
like the liver that emits 12 times less. Lastly, by comparing
the hydrodynamic injected rats with the control and normal
intravenousinjectedrats,themajorityoftheredﬂuorescence
values are higher for hydrodynamic injected rats.
In order to study Ch or Ch-Fa as gene delivery vector,
three groups (each consisted of 3 rats) of the normal Lewis
rats treated with the hydrodynamic intravenous injection
of 200μgn a k e dβ-gal plasmid, Ch-β-gal plasmid DNA,
and Ch-Fa-β-gal plasmid DNA, respectively. Soleus muscles
were isolated and visualized with X-gal expression 3 days
post injection. As shown in Figure 3, the naked DNA can
be expressed (Figure 3(a)2). The Ch-Fa-DNA expression
(Figure 3(a)4) is darkest in the soleus muscle compared
to Ch-DNA expression (Figure 3(a)3). Figure 3(b) showed
soleus muscle histological cross-sectional patterns of β-gal
protein expression stained with its corresponding antibody
after hydrodynamic injection of nanoparticles of Ch-Fa-
plasmidβ-galDNAwithpositivedark-brownstainingwithin
the muscle.
3.4. Eﬃcient Delivery of Ch-Fa-IL-1Ra Plasmid DNA In Vitro
and In Vivo. In vitro, to test the modiﬁcation by adding folic
acid on chitosan backbone, the nanoparticles made of two
types of chitosan were transfected in KB cells with medium
without folic acid supplement. Data showed the signiﬁcantly
higher expressive level in 1640 without folic acid medium
(n = 3, P<. 01) comparing to that in normal medium
(Figure 4(a)). Evidently folic acid in medium interferes the
binding between folate-modiﬁed nanoparticle and cells.
In vivo, as shown in this Figure 4(b), the naked plasmid is
more rapidly expressed in greater quantity in the serum than
the Ch-nano and Ch-Fa-nanoparticles. Despite the longer
time taken by Ch-DNA and Ch-Fa-DNA nanoparticles has
taken the longer time to express themselves in the serum,
but they presented more secreted IL-1Ra proteins at the day
of 34 with compared to naked DNA treated rats. However,
there were no signiﬁcant diﬀerences in the IL-1Ra protein
concentration across the three treatment groups (naked
DNA, Ch-DNA, and Ch-Fa-DNA).
3.5. Eﬃcacy in a Rat Model of Arthritis. Paw swelling.
Decrease in macroscopic inﬂammation in various degrees
in AIA rat’s paws after treatment with Ch-plasmid IL-
1Ra DNA, or Ch-Fa-plasmid IL-1Ra DNA, as shown in
Figure 5(a). There is a decrease in the percentage of ankle
size in all treated groups compared to the untreated RA
positive control group. Only the Ch-Fa-pIL-1Ra group
showed signiﬁcant decrease in ankle size (P<. 05, n =
5). However, there was no signiﬁcant diﬀerence between all
other treatment groups (naked DNA, and Ch-DNA).
LevelsofserumproinﬂammatoryfactorIl-1β andPGE2.To
measure the inﬂammation changes after treatment, cytokine
IL-1β, a potent immunomodulator which mediates a wide
range of immune and inﬂammatory responses, was detected
intheserumoftheexperimentalanimalratmodel.Agradual
increase of cytokine level was seen in the positive control
g r o u p( R A ) ,w h i l et h e r ew a sa na b r u p td e c r e a s eo fI L - 1 β
levelsfollowingtreatmentwithCh-plasmidIL-1RaDNAand
Ch-Fa-plasmid IL-1Ra DNA nanoparticles. This bring to the
fore the inﬂammation reduction, since IL-1Ra competes for
the IL-1 receptor and indirectly decrease IL-1β production
therein (Figure 5(b)). As shown in Figure 5(c),ag r a d u a l
increase of PGE2 levels is seen in the positive control group
(RA) whereas there is a decrease of PGE2 levels following
treatment with Ch-pIL-1Ra. Lower levels of PGE2 synthesis
were observed in all treated groups compared to positive
control.
4. Discussion
The hydrodynamic limb vein injection involves the rapid
injection of a large volume of naked DNA through a
peripheral vein a limb that is temporarily isolate from
normal blood ﬂow by a tourniquet [6–8]. In this study,6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬃcient delivery of Ch-Fa-plasmid IL-1Ra DNA in vitro
and in vivo.( a )In vitro, KB cells received either 5μgo fC h -
plasmid IL-1Ra DNA nanoparticles or Ch-Fa-plasmid IL-1Ra DNA
nanoparticles in the presence or absence of folic acid supplement.
Values are the mean ± SEM. Statistical signiﬁcance was assessed
by unpaired Student t. (b) Three groups (each consisted of 3 rats)
of the normal Lewis rats treated with the hydrodynamic femoral
intravenous injection of 200μgn a k e dβ-gal plasmid, Ch-β-gal
plasmid DNA, and Ch-Fa-β-gal plasmid DNA, respectively. Serum
samples were collected at day 24, 28 and 35, respectively. The levels
of IL-1Ra protein in the cellular cultured media and serum were
analyzedbyELISA.Valueswereshownasmean ±SEMofthreerats.
All values were subjected to t test and one-way ANOVA analysis. A
value of 0.05 was considered signiﬁcant.
we found that the expression of the targeted protein by a
Ch-nanoparticle is possible (as reﬂected by DeRed protein
expression and staining by β-gal in the soleus muscle).
Although hydrodynamic injection causes edema at the site
of puncture (data not show), injection skills may aﬀect
the eﬀect of genetic material delivered [26]. However, in
our study, this manipulation was performed by the same
person, used to the technique, thereby reducing the eﬀect
of the learning curve on the quality of delivery. In addition,
the hydrodynamic injection allows the introduction of high
volume solution into the muscle tissue. This situation allows
for a greater concentration of nanoparticles around cells
suggesting a greater potential of capture through endocy-
tosis. The transfection eﬃciency of nonviral vectors may
depend on several factors such as chemical structure of
polycations, size and composition of complexes, interaction
between cells and complexes and the cell type. The small
size complexes have the advantage of entering the cells
through endocytosis or pinocytosis and crossing the nuclear
pore complex, thereby increasing the transfection rate.
Our results demonstrated that our nanoparticles (average
108nm) obtained favored nanosize. Many researchers [27,
28], including us [29], are actually working on the synthesis
of smaller size nanoparticles.
The hydrodynamic injection showed 5 to 12 times more
red protein ﬂuorescence in the leg muscles in proximity of
the injected femoral vein than the other sampled parts (ex:
kidney). It even goes up to 20 times more when comparing
with the control (ex: left gastro muscle). This is what we
hoped to obtain with the hydrodynamic vein tourniquet
injection. A normal femoral vein injection done using these
same manipulations, the results would not appear much
in the legs, but instead it will mostly be in the rat’s
liver and spread across other body parts. In our case, the
tourniquetmadesothatthesolutiontravelsbackintosmaller
veins and end up in muscle cells. In the case where the
tourniquet is well installed, directing the process towards
good conditions by blocking the escape, the local injection
load is administered gently enough to trap and spread the
injected solution in and not beyond the tourniquet. If some
of the solution gets to escape, it would get ﬁltered, stopped,
in the lungs, liver, kidneys, and aorta, and in most cases,
travel in the blood circulation system. That is why in rat with
normal intravenous injection, we were not able to observe
the leg muscles swelling (data not shown). Instead, the whole
leg got bigger in size, acting like a balloon being blown up.
Probably, the solution was at ﬁrst trapped in the leg due to
the tourniquet applied in the lymphatic and vein drainage
system which stop the solution from spreading beyond the
knee with high pressure. The pressure does so that the
injected solution in the femoral vein stops going forward and
isforcedbackintothesmallerveinsintheoppositedirection.
It has been demonstrated that naked DNA express easily
when injected into a muscle mass [30]. According to the
resultsobtainedthroughβ-galstainingwithX-gal,wecansee
thatwithoutanytreatment,thenakedDNAcanbeexpressed.
When surrounded by a layer of 50kDa chitosan as a nonviral
approach, only ﬁne blue lines can be seen on part of the
targeted soleus leg muscle. This means that the particles
entereddiﬃcultlyintothecellsbeyondtheveinssurrounding
the leg muscle. The answer to where they went is found by
observing the ﬁnal destination of the body ﬂuid circulation,
acting like body “ﬁlter”, the liver [31–33]. Once upgraded
with folic acid (Fa), the results are totally diﬀerent. The
soleusmusclesaresuitablydarkerthanthecontrol.Evidently,Journal of Biomedicine and Biotechnology 7
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Figure 5: Eﬃcacy in a rat model of arthritis. The rats were inoculated intradermally, into the plantar surface of the right hindpaw, with
0.1ml of complete Freund’s adjuvant (CFA) containing 10mgml−1 of heat-killed Mycobacterium tuberculosis suspended in paraﬃn oil. The
rats were allocated to 5 groups. A control group (naked DNA, n = 5), a natural Ch-IL-1Ra plasmid DNA nanoparticles group (n = 5) and
a Ch-Fa-IL-1Ra plasmid DNA nanoparticles group (n = 7) were injected on day 18 post AIA induction. A nontreated group (Rheumatoid
arthritis, RA) (n = 5) was used as an untreated control. All animals were sacriﬁced on day 35 and clinical results were compared among the
groups. (a) Rat’s ankle size change before and after treatments. Graph shows changes of absolute ankle size (mm) in AIA rats before and after
diﬀerent treatments at day 18. Each point represents the mean ± SD. Note a signiﬁcant decreasing inﬂammation with Ch-Fa-Il-1Ra gene
therapy (P ≤ .05, n = 7) comparing to the AIA nontreated control. Diﬀerences observed between all treated groups were nonsigniﬁcant
(NS). (b) IL-1β concentration in rat sera. All treated groups showed signiﬁcant decrease IL-1Ra in serum (P ≤ .05, n = 5) compared to
nontreated controls. It can be clearly seen that this eﬀect is observed the day after treatment starts. Black arrow indicates the day of starting
IL-1Ra gene therapy. (c) PGE2 level in rat sera after Il-1Ra treatment. All values are expressed as means ± SD and were subjected to t test
and one-way ANOVA analysis. A value of 0.05 was considered signiﬁcant. There is a signiﬁcant decrease in the levels of PGE2 in all three
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the intensity is lower in the liver (data not shown). When
observing the hydrodynamic injection technique eﬃciency
rate for this experiment, the injections technical skill play a
very important role.
We observed that IL-1Ra protein expression was signif-
icantly higher (P<. 05) when transfection was prepared
with chitosan-folate-IL-1Ra plasmid DNA complexes in the
culturemedium withoutfolicacidsupplement(Figure 4(a)).
These ﬁndings suggested that folic acid molecules supple-
mented in culture medium would prevent cellular uptake
of the complexes by competitive binding to FRs on the
cell surface. The in vivo study revealed that the IL-1Ra
gene can be transduced in vivo exploiting nonviral chitosan
and folate target technology via hydrodynamic limb vein
injection. The injected muscle was the predominant site of
gene transfer and expression after hydrodynamic limb vein
injection. In our study, Il-1Ra protein expression was also
detected in rat sera. It is interesting to note that IL-1Ra
protein can be detected in the serum of rats as long as
6–17 days following the injections of both chitosan-DNA
and chitosan-folate-DNA nanoparticles, possibly oﬀering
a lasting, sustain release of IL-1Ra in the serum. Folate
conjugation improves the transfection eﬃciencies of FA-
chitosan for FR-positive cell gene silencing in conditions
without folic acid supplement. Because of FR overexpression
in cancer cells and activated macrophages, a variety of
therapeutic agents have been linked with folic acid for
selective delivery to pathological cells, by avoiding normal
tissues. Among these therapies, folate-targeted nonviral gene
therapy vectors are considered as promising treatments of
cancer and inﬂammatory diseases [33–35].
The hydrodynamic limb vein injection technology has
been shown to be eﬀective for the delivery naked DNA
into the skeletal muscle of the limb. This approach has a
good proﬁle for the treatment of muscular disease such as
muscular dystrophy. In this study, the usefulness of hydro-
dynamic delivery to decrease inﬂammation in experimental
arthritis treatment was also demonstrated. The ﬁrst model
of RA to be described was adjuvant arthritis, and the
arthritis develops 10–45 days after injection and generally
subsides after a month [36] .B a s e do no u re x p e r i e n c e sw i t h
adjuvantinducedarthritisinrats,diseaseisallowedtoobtain
maximum inﬂammation around 18 days, as evidenced by
dramatic swelling in the injected paw measurements of
proinﬂammatory biomarkers such as TNF-α and IL-1β.S o
we inject chitosan/folate-chitosan-DNA nanoparticles at day
18 to treat inﬂammation caused by adjuvant injection.Our
resultsshowedthatitispossibletoexpresstheIL-1Raprotein
with a variety of cationic polymeric-based nanoparticles.
Macroscopically, hydrodynamic injection of these nanopar-
ticles in an AIA rat model allow a signiﬁcant decrease of
the inﬂammation in the rats’ ankle compared to untreated
rats, proving indirectly the eﬃcacy of the IL-1Ra protein
treatment. Various inﬂammation markers (IL-1β and PGE2)
showed a signiﬁcant decrease in the muscle and serum after
the injection of the IL-1Ra protein demonstrating by direct
evidence the eﬃcacy of the administration technique to
deliver eﬃcient nanoparticles. Therefore, it is possible to
do gene therapy via hydrodynamic limb vein injection with
IL-1Ra to decrease arthritis and have a positive eﬀect on
inﬂammation.
In conclusion, the eﬃcacy of chitosan-folate-based
nanovectors was conﬁrmed in vitro in KB cells and in vivo
using hydrodynamic delivery of β-gal DNA nanocarriers
in Lewis rats. This study demonstrated the eﬃcacy of
a therapeutic approach (after maximum disease progres-
sion) using hydrodynamic delivery of plasmid IL-1Ra DNA
and chitosan-DNA-based nanocarriers in controlling the
progression of inﬂammation in an AIA rat model. More
research are needed toward the search for smaller and more
performing nanoparticles in the treatment of arthritis using
gene therapy.
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